Focus on Cancer in the Pharmaceutical Pipeline Tracker

According to NIH’s National Cancer Institute, the following chart shows the top thirteen cancer types in the US as of February 2019 sorted by estimated new cases.

In terms of impact on healthcare systems, the top four cancers by estimated new cases represent 57% of new cases within the top thirteen and 61% of the estimated deaths for this group.

Lung Cancer, with the second most frequent occurrence of new cases, is also the deadliest with a 63% mortality rate. Prescribe Right’s Pharmaceutical Pipeline Tracker shows twenty-one investigational drugs focused on Lung Cancer. Seventeen are in Phase III trials. Several of these efforts are focused on multiple cancers. Ten are focused solely on non-small cell lung cancer, six of which are in Phase III trials. 

There are no investigational drugs focused on Lung Cancer within the twenty that have PDUFA Dates between August 27, 2019 and May 14, 2020.

Breast cancer has the most occurrences of new cases and the third lowest mortality rate (16%). Prescribe Right’s Pharmaceutical Pipeline Tracker shows 18 investigational drugs focused on Breast Cancer. Fourteen of the drugs are in Phase III trials. Several of these efforts are focused on multiple cancers including non-small cell lung cancer. 
​
The oncology therapeutic category is the largest therapeutic category within the Pharmaceutical Pipeline Tracker with 133 investigational Oncology drugs.